PURPOSE: To compare morbidity, mortality, recurrence and 5-year survival between D1 and D2 or D3 for treatment of gastric cancer. METHODS: Systematic review and meta-analysis of RCTs. Metaview in RevMan 4.2.8 for analysis; statistical heterogeneity by Cochran's Q test (P50%). Estimates of effect were calculated using random effects model. RESULTS: D2 or D3 was associated with higher in-hospital mortality, with RR = 2.13, p=0.0004, 95% CI, 1.40 to 3.25, I²=0%, P=0.63; overall morbidity showed higher incidence in D2 or D3, RR = 1.98, p<0.00001, 95% CI, 1.64 to 2.38, I² = 33.9%, P=0.20; operating time showed longer duration in D2 or D3, weighted mean difference of 1.05, p<0.00001, 95% CI, 0.71 to 1.38, I² = 78.7%, P=0.03, with significant stat...
BACKGROUND: Very few studies from Western centers have compared D2 and D3 dissection in the surg...
Purpose: To analyze our experience with D3 lymphadenectomy in the treatment of advanced GC with spec...
Although curative resection is the treatment of choice for gastric cancer, controversy exists...
[[abstract]]Background: A randomized comparison of D1 (level 1 lymphadenectomy) and D3 (levels 1, 2 ...
Background: The extent of lymph node dissection in patients with resectable non-metastatic primary c...
BACKGROUND: Gastrectomy including D2 lymphadenectomy is regarded as the standard curative treatment ...
Objective: Postoperative outcome and potential risk factors for complications after D2 and D3 lympha...
Background: In gastric cancer the incidence of loco-regional recurrences decreases when lymphadenect...
BACKGROUND: The survival benefit of extended lymphadenectomy in the surgical treatment of gastric ...
BACKGROUND: In gastric cancer the incidence of loco-regional recurrences decreases when lymphade...
PURPOSE: To analyze our experience with D3 lymphadenectomy in the treatment of advanced GC with ...
Background and Objectives: The optimal extent of lymphadenectomy in the treatment of gastric adenoca...
Background: Although the Japan Clinical Oncology Group (JCOG) 9501 trial did not find that prophylac...
PURPOSE: This study was designed to investigate whether the number of lymph nodes removed offers pro...
Background/Aims: A randomized study was per formed to evaluate morbidity and mortality after D2 (lev...
BACKGROUND: Very few studies from Western centers have compared D2 and D3 dissection in the surg...
Purpose: To analyze our experience with D3 lymphadenectomy in the treatment of advanced GC with spec...
Although curative resection is the treatment of choice for gastric cancer, controversy exists...
[[abstract]]Background: A randomized comparison of D1 (level 1 lymphadenectomy) and D3 (levels 1, 2 ...
Background: The extent of lymph node dissection in patients with resectable non-metastatic primary c...
BACKGROUND: Gastrectomy including D2 lymphadenectomy is regarded as the standard curative treatment ...
Objective: Postoperative outcome and potential risk factors for complications after D2 and D3 lympha...
Background: In gastric cancer the incidence of loco-regional recurrences decreases when lymphadenect...
BACKGROUND: The survival benefit of extended lymphadenectomy in the surgical treatment of gastric ...
BACKGROUND: In gastric cancer the incidence of loco-regional recurrences decreases when lymphade...
PURPOSE: To analyze our experience with D3 lymphadenectomy in the treatment of advanced GC with ...
Background and Objectives: The optimal extent of lymphadenectomy in the treatment of gastric adenoca...
Background: Although the Japan Clinical Oncology Group (JCOG) 9501 trial did not find that prophylac...
PURPOSE: This study was designed to investigate whether the number of lymph nodes removed offers pro...
Background/Aims: A randomized study was per formed to evaluate morbidity and mortality after D2 (lev...
BACKGROUND: Very few studies from Western centers have compared D2 and D3 dissection in the surg...
Purpose: To analyze our experience with D3 lymphadenectomy in the treatment of advanced GC with spec...
Although curative resection is the treatment of choice for gastric cancer, controversy exists...